Literature DB >> 23262207

HPV-type has no impact on survival of patients with adenocarcinoma of the uterine cervix.

Astrid Baalbergen1, Frank Smedts, Patricia Ewing, Peter J F Snijders, Chris J L M Meijer, Theo J M Helmerhorst.   

Abstract

OBJECTIVE: To review and characterise by clinical evaluation, immunohistochemistry and HPV typing a group of adenocarcinomas initially diagnosed with primary localisation in the cervix. Furthermore, to assess the prevalence and prognostic significance of HPV genotypes in a large series of HPV positive cervical adenocarcinomas (AC).
METHODS: One hundred and seventy-one cases of adenocarcinomas (AC) with a primary localisation in the cervix and diagnosed between 1989 and 2008 in the region of Rotterdam, the Netherlands were retrieved. Slides and blocks were reviewed and immunohistochemically stained for CEA and vimentin. HPV testing for high-risk HPV (hrHPV) by PCR (GP5+/6+) and genotyping by reversed line blot were performed.
RESULTS: In 113 of 171 patients HPV evaluation was possible. 101 were HPV-positive (89%) and 11 were HPV-negative (11%). The 5-year disease free survival was 80% in the HPV-positive group versus 74% in the HPV-negative group (ns). The distribution of HPV types was type 18 in 55 patients (54%), type 16 in 37 (37%), type 45 in 7 (7%), types 53 and 39 were found in 2 respective patients. 5-year overall-survival in patients with HPV-18 was not significantly worse than in patients with HPV-16 (81 versus 87%). Patients with HPV-45 had a worse 5-year survival, 57%.
CONCLUSIONS: AC is hrHPV related in most cases (89%) and HPV-18 is the most frequent type (54%). With the exception of HPV-45, HPV-positivity or type in endocervical AC has no significant influence on survival.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23262207     DOI: 10.1016/j.ygyno.2012.12.013

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  6 in total

1.  A chimeric 18L1-45RG1 virus-like particle vaccine cross-protects against oncogenic alpha-7 human papillomavirus types.

Authors:  Bettina Huber; Christina Schellenbacher; Christoph Jindra; Dieter Fink; Saeed Shafti-Keramat; Reinhard Kirnbauer
Journal:  PLoS One       Date:  2015-03-19       Impact factor: 3.240

2.  Surgical staging identified false HPV-negative cases in a large series of invasive cervical cancers.

Authors:  Karl Ulrich Petry; Clemens Liebrich; Alexander Luyten; Martina Zander; Thomas Iftner
Journal:  Papillomavirus Res       Date:  2017-10-19

3.  Human papillomavirus genotype and prognosis of cervical cancer: Favorable survival of patients with HPV16-positive tumors.

Authors:  Mamiko Onuki; Koji Matsumoto; Yuri Tenjimbayashi; Nobutaka Tasaka; Azusa Akiyama; Manabu Sakurai; Takeo Minaguchi; Akinori Oki; Toyomi Satoh; Hiroyuki Yoshikawa
Journal:  Papillomavirus Res       Date:  2018-10-19

4.  Human papilloma virus genotyping for the cross-sectional and longitudinal probability of developing cervical intraepithelial neoplasia grade 2 or more.

Authors:  Annarosa Del Mistro; Rachael Adcock; Francesca Carozzi; Anna Gillio-Tos; Laura De Marco; Salvatore Girlando; Raffaella Rizzolo; Helena Frayle; Morena Trevisan; Cristina Sani; Elena Burroni; Paolo Giorgi Rossi; Jack Cuzick; Guglielmo Ronco
Journal:  Int J Cancer       Date:  2018-03-09       Impact factor: 7.396

5.  Population-Based Assessment of HPV Genotype-Specific Cervical Cancer Survival: CDC Cancer Registry Sentinel Surveillance System.

Authors:  Benjamin D Hallowell; Mona Saraiya; Trevor D Thompson; Elizabeth R Unger; Charles F Lynch; Tom Tucker; Glenn Copeland; Brenda Y Hernandez; Edward S Peters; Edward Wilkinson; Marc T Goodman
Journal:  JNCI Cancer Spectr       Date:  2018-08-11

6.  Genomic alterations caused by HPV integration in a cohort of Chinese endocervical adenocarcinomas.

Authors:  Wenhui Li; Wanjun Lei; Xiaopei Chao; Xiaochen Song; Yalan Bi; Huanwen Wu; Ming Wu; Lei Li
Journal:  Cancer Gene Ther       Date:  2021-01-04       Impact factor: 5.987

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.